West Family Investments Inc. Takes $794,000 Position in Cencora, Inc. $COR

West Family Investments Inc. bought a new position in Cencora, Inc. (NYSE:COR) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 2,805 shares of the company’s stock, valued at approximately $794,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Kemnay Advisory Services Inc. purchased a new position in shares of Cencora during the fourth quarter worth approximately $25,000. Oakworth Capital Inc. purchased a new stake in shares of Cencora in the 4th quarter valued at $26,000. Elyxium Wealth LLC purchased a new stake in shares of Cencora in the 4th quarter valued at $27,000. Elevation Wealth Partners LLC grew its holdings in shares of Cencora by 506.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 97 shares of the company’s stock valued at $27,000 after purchasing an additional 81 shares during the last quarter. Finally, Archer Investment Corp grew its holdings in shares of Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after purchasing an additional 47 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Shares of NYSE COR opened at $316.78 on Thursday. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54. The stock has a market capitalization of $60.45 billion, a P/E ratio of 23.53, a P/E/G ratio of 1.81 and a beta of 0.57. The company’s 50-day moving average is $301.20 and its 200 day moving average is $312.16. The company has a debt-to-equity ratio of 3.53, a current ratio of 0.93 and a quick ratio of 0.58.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, topping the consensus estimate of $4.35 by $0.13. The business had revenue of $84.75 billion during the quarter, compared to analyst estimates of $84.31 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. Cencora’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period last year, the business posted $4.00 earnings per share. On average, sell-side analysts expect that Cencora, Inc. will post 17.87 earnings per share for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Friday, August 14th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Friday, August 14th. Cencora’s dividend payout ratio (DPR) is presently 17.83%.

Cencora declared that its Board of Directors has approved a stock repurchase plan on Thursday, May 21st that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to reacquire up to 3.9% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

COR has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Barclays cut their price target on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. Bank of America lifted their price objective on Cencora from $280.00 to $285.00 and gave the stock a “neutral” rating in a report on Wednesday, June 24th. Wells Fargo & Company lifted their price objective on Cencora from $331.00 to $395.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Finally, Citigroup reissued a “buy” rating on shares of Cencora in a research note on Thursday, August 6th. Thirteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $370.85.

Insider Activity at Cencora

In other news, Director Lauren M. Tyler purchased 550 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were bought at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the transaction, the director directly owned 4,359 shares of the company’s stock, valued at $1,177,932.57. This trade represents a 14.44% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.38% of the stock is currently owned by insiders.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.